Clinical Trial Update: NEoadjuvant Olaparib Combination OvArian Cancer Targeted Study [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial evaluating Olaparib in ovarian cancer (Stage IV) is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Ovarian Cancer Stage IV | Phase 2 | Status: NOT_YET_RECRUITING